Xencor doses first subject in early-stage XmAB564 autoimmune disease study

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Xencor doses first subject in early-stage XmAB564 autoimmune disease study

To read the full story on Seeking Alpha, click here.

Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Aug 2024 to Sep 2024

Click Here for more Xencor Charts.

Xencor (NASDAQ:XNCR)
Historical Stock Chart
From Sep 2023 to Sep 2024

Click Here for more Xencor Charts.

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Share on Facebook Share on Twitter Share on Email

Loading Messages....

See More Message Board Posts

Xencor Inc News

More Xencor Inc News Articles

Impact Fusion (PK)

Brookmount Explorations (PK)

Branded Legacy (PK)

TransCode Therapeutics

NaturalShrimp (QB)

Mullen Automotive

CyberFuels (PK)

Enzolytics (PK)

Valiant Eagle (PK)

1812 Brewing (PK)

Healthier Choices Manage... (PK)

Intergrated Cannabis Sol... (PK)

Delayed Upgrade Clock